Skip to content
Screener

Nuvation Bio NUVB Research And Development Service Revenue — Deferred Revenue

Other product segments

License
$58.7M

Similar metrics at other companies

Pure Cycle logo
PCYOLand Development — Deferred Revenue
$2.75M+180%
Cinemark Holdings logo
CNKOther Deferred Revenues — Deferred Revenue
$261.1M+5.8%
A10 Networks logo
ATENServices — Deferred Revenue
$137.37M-0.7%
Ooma logo
OOMASubscription And Services — Deferred Revenue
$17.03M+6.6%
Duos Technologies Group, Inc. logo
DUOTServices And Consulting — Deferred Revenue
$166.45K
Xponential Fitness logo
XPOFFranchise Development Fees — Deferred Revenue
$73.73M+113,323%

Other financials

Income statement

See full
Revenue$31.7M+556%
Gross profit$9.8M+1,340%
Operating income-$51.0M+19.7%
Net income-$62.8M-6.5%
EPS (diluted)-$0.18-5.9%

Balance sheet

See full
Cash & equivalents$258.6M+4.3%
Total debt$9.5M-83.5%
Total equity$253.9M-31.9%
Total assets$744.5M+15.0%

Cash flow

See full
Operating cash flow-$43.0M+10.8%
CapEx$254.0K+40.3%
Free cash flow-$43.2M+10.6%

Valuation

See full
Market cap$2.32B+202%
Enterprise value$2.07B+259%
P/S13.6×-39.8×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-81%-39.4pp
Net margin-88.2%-42.7pp
FCF margin-75.7%-36.6pp

Returns & leverage

See full
Return on equity-47.8%-9.8pp
Debt / equity-0.1×
Current ratio8.4×-1.0×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:55 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336646

When a customer pays consideration before the Company provides services, the Company records its obligation as a contract liability representing the transaction price allocated to the remaining performance obligations. The contract liabilities as of June 30, 2026 of $17.0 million consists of $0.3 million of deferred revenue which will be recognize as product revenue and the remaining $16.7 million are expected to be recognized as revenue as research and development services are provided over the next 3 years, with $8.5 million expected to be recognized within one year of the balance sheet date.

Item 1. Financial Statements.

FAQ

What is Nuvation Bio's research and development service revenue — deferred revenue?
Nuvation Bio (NUVB) reported research and development service revenue — deferred revenue of $17M in Q2 2026.
How has Nuvation Bio's research and development service revenue — deferred revenue changed year-over-year?
Nuvation Bio's research and development service revenue — deferred revenue decreased by 23.4% year-over-year, from $22.18M to $17M.
What does research and development service revenue — deferred revenue mean?
This represents the obligation to provide research and development services to a customer for which the company has already received consideration or has an unconditional right to consideration. It serves as a measure of deferred revenue that will be recognized as performance obligations are satisfied over time. A high balance indicates significant future service commitments and potential revenue visibility.

Ask your AI about Nuvation Bio's research and development service revenue — deferred revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude